INTRODUCTION
The heterogenous nature of circulating parathyroid hormone (PTH)l is well recognized (1) (2) (3) (4) (5) (6) . However, Dr. Martin was a recipient of a National Kidney Foundation fellowship during these studies.
Received for publication 28 August 1975 and in revised form 31 March 1977. 'Abbreviations used in this paper: COOH terminal, carboxy terminal; GFR, glomerular filtration rate; NH2 terminal, amino terminal; PTH, parathyroid hormone; b-PTH 1-84, the origin and biological significance of the various hormonal fragments found in the circulation remains to be determined. Evidence for a role of the liver and the kidney in the degradation of PTH and the production of PTH fragments has been obtained. Studies with the isolated perfused rat liver demonstrated degradation of intact bovine PTH (b-PTH 1-84) and appearance of PTH fragments in the perfusion fluid (7) . Studies in awake dogs with indwelling hepatic vein catheters demonstrated selective uptake of intact b-PTH 1-84 by the liver and production of carboxyl terminal (COOH terminal) fragments (8) . No hepatic uptake of PTH fragments, either carboxyl or amino terminal (NH2 terminal) could be demonstrated.
The kidney can extract intact PTH and both COOHand NH2-terminal fragments from the circulation (9) .
The uptake mechanism for intact PTH and the biologically active NH2-terminal fragment (syn b-PTH 1-34) seems to involve both glomerular filtration and peritubular uptake (10) . In contrast, renal uptake of COOHterminal fragments could not be demonstrated in the absence of glomerular filtration suggesting that filtration with subsequent tubular reabsorption and degradation is the major disposal route of COOHterminal PTH fragments in the organism.
Direct evidence for production of PTH fragments by the kidney was not obtained during the in vivo studies on the renal uptake of PTH. In addition, a clear effect of changes in plasma calcium concentrations on the disappearance of immunoreactive PTH intact bovine PTH; i-PTH, immunoreactive PTH; syn b-PTH 1-34, biologically active amino terminal fraction of bovine PTH; RIA, radioimmunoassay; TRP, fractional phosphate reabsorption. phosphorus, magnesium, and bicarbonate were maintained at physiological levels. After the institution of perfusate flow, there was an initial period of vasoconstriction lasting 10-15 min during which time renal blood flow was relatively low (100-150 ml/min), urine flow rates were usually less than 1.0 ml/min, and glomerular filtration rate (GFR) values were less than 10-15 ml/min. Subsequently, renal blood flow increased spontaneously, requiring increased perfusion rates to maintain normal perfusate systolic pressures. After the necessary adjustments, as vasoconstriction disappeared, renal blood flow, urine flow rates, GFR, and electrolyte excretion rates were fouind to be constant for approximately 2 h. Deterioration of renal function was heralded by a water diuresis with uirine flow rates reaching 2-5 ml/min just before a decrease in GFR was detected.
Study protocol. During the period of stable renal function, 100 gg of b-PTH 1-84 was injected rapidly through an arterial injection port into the kidney perfusate. Sequential blood and urine samples were then collected every 5-10 min for determination of renal function and characterization of circulating i-PTH. Perfusate ionized calcium concentrations were maintained at 4.0-4.9 mg/dl in most experiments. In those experiments in which the effect of calcium on PTH degradation rates was studied, calcium concentrations were either lowered to 1-2 mg/dl by the addition of EDTA to one-half of the collected perfusate before its addition to the perfusion apparatus or increased to 5.6-7.0 mg/dl by the addition of calcitum gluconate to the other half of the collected perfusate.
Perfusate sample handling. Perfusate samples collected before and after the addition of b-PTH 1-84 to the renal perfusion system were divided in two portions. One portion was centrifuged immediately, and the chemical determinations described below were performed. The other portion of the perfu-sate sample was placed immediately in ice and centrifuged at 4°C, and the plasma was separated from the erythrocytes and frozen until gel filtration was performed. Gel filtration. Samples of renal perfusate (1.5 ml), collected at varying times after the addition of b-PTH 1-84 to the perfusion system, were filtered in 1.5 x 50-60-cm columns of Sephadex G-50 fine (Pharmacia Fine Chemicals, Inc., Uppsala, Sweden). The gel columns were characterized by the elution positions of dextran blue (void volume), 1251 (salt volume), 125I-b-PTH 1-84, and 125I-syn b-PTH 1-34. The elution buffer was 0.15 M ammonium acetate with 1% human plasma added.2 The pH of the final column buffer was adjusted to 5.5. Sephadex gels were prepared by swelling dry beads in water and heating to 900C for 1 h. Swollen beads were then placed in the cold (40C) for 24 h before degassing for 2 h also at 4°C. The beads were then added to the columns and equilibrated with the ammonium acetate-1% plasma buffer for 72 h by constant running with gravitydriven flow with a pressure of 9-10 cm H20. Column flow rate was 7-8 ml/h. All gel filtration studies were performed at 4°C, and column eluate fractions of 0.5 ml were collected. Both COOH-and NH2-terminal i-PTH were determined in the eluate fractions as described below. Recoveries of 1251-b-PTH 1-84 and 1251-syn b-PTH 1-34 ranged from 90 to 95%.
Radioimmunoassay methods. Samples of column eluates were assayed for both COOH-and NH2-terminal i-PTH by radioimmunoassay (RIA) techniques previously described (8, 9) . In the present studies, the CH9 antiserum was used in RIAs for COOH-terminal immunoreactivity in a final dilution of 1:80,000. This antiserum is predominantly COOHterminal specific (9) , and its preincubation with excess syn b-PTH 1-34 did not change the elution profile of i-PTH in column eluates assayed with this antiserum. NH2-terminal i-PTH was determined utilizing the CH9N antiserum produced against syn b-PTH 1-34 and specific for NH2-terminal PTH binding sites in a final dilution of 1:8,000. 50-to 200-/l samples of each column eluate fraction were incubated with the appropriate antisera at 40C with constant shaking for 72 h before the addition of 125I-syn b-PTH 1-34. lodination of peptides with 1251 was by the method of Greenwood et al. (11) as previously reported (9) . The specific activities of these tracer peptides ranged from 250 to 450 ACi/,lg for 1251-b-PTH 1-84 and from 150 to 250 ,uCi/,ug for 1251-syn b-PTH 1-34. Separation of free from bound counts by charcoal-coated dextran, radioactivity counting, and calculations were performed as described previously (8) . Corrections for the effect of column buffer on the antigenantibody reaction were performed in each assay by adding an appropriate volume of column buffer, equal to the volume of the column fraction being assayed, to control tubes for nonspecific binding, tracer binding tubes, and standard curve tubes. The effect of these buffer additions compared to assay tubes without column buffer added was insignificant. The pH of the assay mixture with 200 ,ul of column buffer was 8.2 compared to 8.6 for the standard assay mixture.
Chemical determinations. Creatinine, phosphorus, and para-aminohippurate were determined by methods described previously (12) (13) (14) . Magnesium and calcium concentrations were determined by atomic absorption spectrophotometry and ionized calcium with a calcium specific electrode (Orion Research Inc., Cambridge, Mass.).
Sources of PTH. "Highly purified" b-PTH 1-84 for injection into the renal perfusate, standard curves and iodination was purchased from Inolex Corp., Biomedical Division (Glenwood, Ill.). The b-PTH 1-84 had a specific biological activity of 1,000-1,500 U/mg in a rat bioassay. syn b-PTH 1-34 with a specific activity of 3,400-3,700 IU/mg in the renal adenylate cyclase system was obtained from Beckman Instruments, Inc., Fullerton, Calif. Additional experiments were performed with purified b-PTH, a generous gift of Dr. Howard Rasmussen. In these experiments, this PTH served as the labeled tracer, standard curve preparation, and as the PTH for injection into the renal perfusate.
RESULTS
Functional parameters of the isolated perfused kidneys. The electrolyte composition of the renal perfusate and the functional characteristics of 11 isolated perfused kidneys are presented in Table I Fig. 1 . This tracer material was prepared as described above, and previously (9) , and separated from free iodine and iodination damage products by absorption onto and elution from Quso G-32 (Philadelphia Quartz Co., Philadelphia, Pa.) followed by gel filtration on 1 x 20-cm columns of Bio-Gel P-10 (Bio-Rad Laboratories, Richmond, Calif.). Only a single peak of radioactivity was observed in the column fractions. Also shown in Fig. 1 relationship between GFR and degradation of b-PTH 1-84 and the disappearance of the produced fragments was studied by comparing the elution patterns of i-PTH in perfusates obtained from kidneys with varying GFRs. The i-PTH elution patterns in Fig. 3 on the left were obtained after 15 and 30 min of renal perfusion after the addition of 100 ,ug b-PTH 1-84 to kidney 2, GFR 40 ml/min. The i-PTH elution patterns on the right of the figure were obtained from kidney 4, GFR 13 ml/min, in experiments performed under identical conditions. The amount of i-PTH eluting with the 1251-b-PTH marker at 30 min was less in the perfusate of kidney 2. This indicates a greater renal clearance for b-PTH 1-84 in the kidney with the higher GFR. The qualitative appearance of the later eluting peaks of i-PTH were similar in that after 15 and perfused on separate perfusion apparatus. The ionized calcium in the perfusate of one of the paired kidneys was decreased to 1-2.4 mg/dl by the addition of sufficient EDTA (kidneys 7, 9, and 11 in Table I ). Calcium gluconate was added to the perfusate of the other kidney in the pair sufficient to raise ionized calcium to 5.6-7.0 mg/dl (kidneys 6, 8, and 10 in Table I ). Only mild degrees of hypercalcemia were employed in an attempt to avoid any effects of hypercalcemia on the GFR and renal plasma flow of the perfused kidney. Fig. 4 shows the elution patterns of COOH-and NH2-terminal i-PTH from perfusate samples collected from kidneys 7 and 6 and gel filtered as described before. The i-PTH eluting with the 125I-b-PTH 1-84 marker disappeared rapidly from the perfusate of the hypocalcemic kidney (left panels). When the elution pattems on the top left and top right of Fig. 4 Because the GFR of the hypercalcemic kidney shown in Fig. 4 was somewhat less than that of the hypocalcemic kidney, milder extremes of altered Ca++ concentrations were studied to further analyze the role of Ca++ in the degradation of b-PTH 1-84. Also, a different source of PTH was used in these experiments to further exclude any possibility that the minor contaminants found in the PTH preparation used in the studies shown in Figs. 1-4 contributed to the observed appearance of i-PTH fragments in the renal perfusate. An experiment similar to that portrayed in Fig. 1 is shown on the top left panel of Fig. 5 . The 1251-b-PTH 1-84 (0 O) tracer eluted as a single peak. The Rasmussen PTH also eluted as a single peak, demonstrating absence of the trace contaminants from the descending slope of the elution pattern that were shown in Fig. 1 . Incubation of b-PTH 1-84 with a renal perfusate sample obtained after 30 min of perfusion at 37°C for 20 min again failed to result in any degradation of the hormone. The middle and bottom panels of Fig. 5 show experiments similar to those, shown in Fig. 4 except that the changes in Ca++ were less extreme. The effect of the milder hypercalcemia on retarding the degradation of b-PTH 1-84 was less and (or) conversely, the effect of milder hypocalcemia on enhancing the degradation of b-PTH 1-84 was less than shown in the experiments in Fig. 4 and others not shown. Nevertheless, a faster disappearance of i-PTH eluting with the 1251-intact hormone is shown when the hypocalcemic perfusate was used. Thus, this experiment again demonstrates degradation of b-PTH 1-84 by the perfused isolated dog kidney, and the appearance and disappearance of smaller molecular weight forms of i-PTH utilizing a second and purer PTH preparation. Also, low perfusate calcium concentrations were again associated with more rapid intact hormone renal clearance and degradation. The effect of hypercalcemia and hypocalcemia appears to be directly related to the degree of alterations in the Ca++ concentration, the greater the alteration the greater retardative (hypercalcemia) or stimulatory (hypocalcemia) effect on b-PTH 1-84 disappearance rate.
DISCUSSION
The results obtained demonstrate that the isolated perfused dog kidney can degrade b-PTH 1-84 with eventual disappearance of the peptide from the perfusion fluid. The lack of degradation of b-PTH incubated with fluid from perfused kidneys suggest that release of nonspecific degradative enzymes into the perfusion circulation from the kidney was not responsible for the results obtained. The similar gel filtration elution profiles of b-PTH 1-84 and samples of b-PTH 1-84 incubated with fluid used to perfuse a kidney for 15 min (Fig. 1 ) also excluded the possibility that small amounts of late eluting contaminants in the original PTH preparation accounted for any of the observed changes in the elution profile of renal perfusate, especially the appearance of any PTH degradation products.
The disappearance of intact b-PTH 1-84 from the kidney perfusate was associated with the appearance of late eluting fragments of i-PTH with both COOHand NH2-terminal binding specificities. These fragments were cleared from the circulation by the perfused kidney as shown by comparing the elution patterns of renal perfusate obtained at 10 or 15 min vs. 30 min after addition of PTH to the perfusion circuit.
The late eluting i-PTH degradation products described in the present studies have the gel filtration characteristics ofthe circulating i-PTH fragments found in vivo after the injection of b-PTH 1-84 into dogs (8, 9) . They are also compatible with the i-PTH fragments reported to be produced by the isolated rat liver (7) and those found in the plasma of hyperparathyroid subjects (2) . Specifically, a small amount of circulating NH2-terminal i-PTH, that eluted in the area of the 125I-syn b-PTH 1-34 marker, was evident in the perfusate of the isolated kidneys shortly after addition of b-PTH 1-84. This demonstrates that the kidney could potentially produce an NH2-terminal fragment in the process of PTH degradation with similar gel filtration characteristics to the NH2-terminal fragment shown in dogs in vivo (9) .
At least two peaks of C-terminal i-PTH appeared in the elution profiles after the peak of intact hormone. Again, these results are similar to COOH-terminal elution patterns found by gel filtration of dog plasma obtained after injection of b-PTH 1-84 in vivo (8, 9) . The The present studies also demonstrate that there is greater accumulation of COOH-terminal i-PTH fragments in the perfusate of kidneys with low GFR. This is compatible with the concept that glomerular filtration is the major means of renal uptake for C-terminal fragments as demonstrated by the lack of COOHterminal fragment uptake in nonfiltering kidneys in vivo. Thus, the absence of accumulation of C-terminal fragments in the perfusate of kidneys with high GFR (right side panels, Fig. 3 ) indicates rapid clearance of these peptides by glomerular filtration.
The effect of calcium on the renal degradation of b-PTH 1-84 was also shown. Calcium concentrations in the perfusate of 5.5 mg/dl or greater were associated with a slower disappearance of b-PTH 1-84, such that at 30 min postinjection intact PTH was still the predominant i-PTH species in the perfusate. In contrast, Ca++ concentrations below 2.4 mg/dl were associated with rapid disappearance of b-PTH from perfusate samples. This effect of calcium concentration differed from that of GFR in that the rapid disappearance of intact hormone observed with very low perfusate calcium concentrations was associated with the accumulation of COOH i-PTH fragments. In contrast, high rates of GFR predominantly increased the disappearance rate of COOH-terminal fragments. Thus, the differences in GFR between the kidney with high and low calcium perfusates in Fig. 4 could not account for both rapid disappearance of intact hormone and accumulation of COOH-terminal i-PTH fragments. These results are in agreement with the effects of calcium on PTH degradation by isolated rat liver (7) and by peptidases in vitro (16) .
The present studies demonstrate production of smaller molecular weight i-PTH fragments during the degradation of intact b-PTH 1-84. The liver (7, 8) and kidney have been shown to produce PTH fragments and to degrade all of the intact hormone added to these isolated organ perfusion circuits within a short time. These studies do not exclude the possibility that circulating PTH fragments in vivo can originate from direct secretion by the parathyroid glands as suggested by other authors (6, 17, 18) . They do suggest that significant fractions of the circulating fragment pool may result from degradation of intact hormone by the kidney.
The present studies also do not elucidate the biological significance of the fragments produced in the various experimental settings discussed above and in vivo. They do support the observation that COOHterminal fragments are dependent upon glomerular filtration and tubular reabsorption for their degradation. This finding may explain the marked retention of COOH-terminal fragments observed in chronic renal failure as GFR falls.
